Copaxone Sales Will Continue Growth Regardless Of Tysabri Re-Launch, Teva Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva expects sales of its multiple sclerosis therapy Copaxone (glatiramer)to continue to grow in 2006 regardless of whether FDA allows the re-launch of competitor Tysabri (natalizumab)